A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Item 1. BUSINESS LadRx Corporation (“LadRx” the “Company”, “we”, “us”, or “our”) is a biopharmaceutical research and development company specializing in oncology. The Company’s focus is on the discovery, research and clinical development of novel anti-cancer drug candidates that employ novel technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. During 2017, LadRx’s discovery laboratory in Freiburg, Germany, synthesized and tested over 75 rationally designed drug conjugates with highly potent anti-cancer payloads, culminating in the creation of two distinct classes of compounds. Four lead candidates (LADR 7 through LADR-10) were selected based on in vitro and animal studies in several different cancer models, stability, and manufacturing feasibility. In addition, a novel companion diagnostic, ACDx™, was developed to identify patients with cancer who are most likely to benefit from treatment with these drug candidates.
| Metric | TTM | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | 0 | 0 |
| Net Income | 0 | -7.2M | -13M | -35M | -51M | -59M |
| EPS | $0.00 | $-0.22 | $-0.41 | $-1.46 | $-3.78 | $-5.82 |
| Free Cash Flow | 0 | -5.7M | -11M | -27M | -51M | -48M |
| ROIC | - | -47.1% | -41.9% | -46.3% | -65.8% | -74.6% |
| Gross Margin | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt/Equity | 0.00 | 0.13 | 1.01 | 0.58 | 0.97 | 0.00 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | 0 | -7.9M | -8.2M | -28M | -52M | -63M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | -40.3% | -66.0% | -163.0% | -147.5% | -104.6% |
| Shares Outstanding | 33M | 33M | 31M | 24M | 13M | 66M |
LadRx Corp passes 0 of 9 quality checks, indicating weak fundamentals.
LadRx Corp (LADX) has a 5-year average return on invested capital (ROIC) of -55.1%. This is below average and may indicate limited pricing power.
LadRx Corp (LADX) has a market capitalization of $326K. It is classified as a small-cap stock.
LadRx Corp (LADX) does not currently pay a regular dividend.
LadRx Corp (LADX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
LadRx Corp (LADX) generated $-6 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
LadRx Corp (LADX) has a debt-to-equity ratio of 0.13. This indicates a conservatively financed balance sheet.
LadRx Corp (LADX) reported earnings per share (EPS) of $-0.22 in its most recent fiscal year.
LadRx Corp (LADX) has a return on equity (ROE) of -40.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 11 years of financial data for LadRx Corp (LADX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LadRx Corp (LADX) has a book value per share of $0.47, based on its most recent annual SEC filing.
No recent press releases.